Chronic Spontaneous Urticaria

A rare case shows HAE with chronic spontaneous urticaria; non-itchy facial swelling despite omalizumab signals C4 and C1-INH testing.

Two oral BTK inhibitors and two injectable biologics demonstrated superior efficacy over placebo in a systematic review of 16 CSU trials.

A study shows physician counseling boosts safe adherence and curbs misinformation-driven decisions, as pregnant women often stop skin treatments and experience worsened symptoms.

Omar Noor, MD, shares pearls on type 2 inflammation, including dupilumab insights for atopic dermatitis, prurigo nodularis, and CSU at Horizons in Advanced Practice.

Nicholas Brownstone, MD, and other experts spotlighted cytokine hubs at the 2026 Winter Clinical Miami conference, linking chronic spontaneous urticaria and psoriasis/psoriatic arthritis to smarter targeted treatment choices.

Barzolvolimab is a humanized monoclonal antibody that inhibits the KIT receptor, aiming to reduce mast cell survival and activity in chronic spontaneous urticaria.

Novartis reports RemIND phase 3 success and submits a supplemental New Drug Application to the FDA for symptomatic dermographism.

Septerna to share phase 1 SEP-631 results at AAAAI, targeting MRGPRX2 to curb mast cell flares and broaden options for refractory CSU.

Review identifies clinical and lab predictors of early antihistamines CSU and omalizumab CSU response, guiding personalized treatment.

In omalizumab-resistant chronic spontaneous urticaria (CSU), tofacitinib rapidly calmed symptoms, but relapses varied.

Clinicians assess chronic urticaria prevalence and impact, revealing gaps in understanding and treatment that affect patient care and outcomes.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!

CSU significantly impacts family quality of life, revealing the need for comprehensive care and support for both patients and their caregivers.

Jasper Therapeutics reveals promising briquilimab data, showcasing rapid disease control and safety in chronic spontaneous urticaria and chronic inducible urticaria.

Discover the latest advancements in CSU treatment, including new therapies and evolving management strategies for better patient outcomes.

A mother shares her personal journey with her daughter's chronic spontaneous urticaria, highlighting the emotional and treatment challenges faced by families.

A study reveals stress coping strategies and eosinophil levels impact CU in adolescents, highlighting the need for integrated psychological support.

Early-phase development introduces a potential first-in-class oral approach targeting type 2 inflammation relevant to dermatologic diseases.

Explore the long-term efficacy and safety of ligelizumab for CSU, highlighting self-administration success and significant symptom control.

Explore the latest advancements in chronic spontaneous urticaria (CSU) therapies, including innovative treatments and patient-centered management strategies.

Celldex is launching a phase 3 trial for barzolvolimab, targeting cold urticaria and symptomatic dermographism, offering hope for effective treatment options.

Discover the potential of INF904, a groundbreaking oral therapy targeting C5aR for hidradenitis suppurativa and chronic spontaneous urticaria, promising new treatment options.

The first-in-class mast cell–selective c-Kit inhibitor ALY-301 enters clinical testing for cold urticaria in Germany.

The topline data support advancing INF904 into larger, controlled trials as a potential convenient alternative to injectable biologics.

Discover the latest advancements in CSU therapy, including Gil Yosipovitch's insights on barzolvolimab's promising results and its potential impact on patient care.